Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.88 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.83 |
| ▸ | HTT | P42858 | 2/20 | 0.83 |
| ▸ | MAPT | P10636 | 1/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.71 |
| ▸ | POLB | P06746 | 2/20 | 0.71 |
| ▸ | HPGD | P15428 | 1/20 | 0.71 |
| ▸ | NPC1 | O15118 | 1/20 | 0.70 |
| ▸ | GAA | P10253 | 1/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | PKM | P14618 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4210314 | 0.93 | TSHR (1.00) | TSHRALDH1A1HTTMAPTCYP3A4 | |
| SCHEMBL4206912 | 0.92 | TSHR (0.88) | TSHRALDH1A1HTTMAPTCYP3A4 | |
| SCHEMBL4214191 | 0.91 | TSHR (0.86) | TSHRALDH1A1HTTMAPTCYP3A4 | |
| SCHEMBL4197640 | 0.91 | TSHR (0.86) | TSHRALDH1A1HTTMAPTCYP3A4 | |
| SCHEMBL18559073 | 0.91 | ALDH1A1 (1.00) | TSHRALDH1A1HTTMAPTCYP3A4 | |
| SCHEMBL4209053 | 0.90 | TSHR (0.84) | TSHRALDH1A1HTTMAPTCYP3A4 | |
| SCHEMBL4210220 | 0.89 | TSHR (0.82) | TSHRALDH1A1HTTMAPTCYP3A4 | |
| SCHEMBL4200834 | 0.87 | TSHR (0.79) | TSHRALDH1A1HTTMAPTCYP3A4 | |
| SCHEMBL18559330 | 0.87 | TSHR (0.79) | TSHRALDH1A1HTTMAPTCYP3A4 | |
| SCHEMBL4198177 | 0.84 | TSHR (0.68) | TSHRALDH1A1HTTMAPTCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264412-A1 | Combination Therapy Using An 11beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor And A Glucocorticoid Receptor Agonist To Minimize The Side Effects Associated With Glucocorticoid Receptor Agonist Therapy | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-10-22 | — | — | US | claimed |
| US-20090137574-A1 | Combination Therapy Using an 11Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor and an Antihypertensive Agent for the Treatment of Metabolic Syndrome and Related Diseases and Disorders | NOVO NORDISK A/S (DK) | 2009-05-28 | — | — | US | claimed |
| US-20060111348-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders | NOVO NORDISK A/S (DK) | 2006-05-25 | — | — | US | claimed |
| US-20060100235-A1 | Pharmaceutical use of substituted 1,2,4-triazoles | NOVO NORDISK A/S (DK) | 2006-05-11 | — | — | US | claimed |
| US-20060094699-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy | HIGH POINT PHARMACEUTICALS, LLC | 2006-05-04 | — | — | US | claimed |
| EP-1615666-A2 | COMBINATION OF AN 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND AN ANTIHYPERTENSIVE AGENT | NOVO NORDISK A/S (DK) | 2006-01-18 | — | — | EP | claimed |
| EP-1615667-A2 | COMBINATIONS OF AN 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST | NOVO NORDISK A/S (DK) | 2006-01-18 | — | — | EP | claimed |
| EP-1615637-A1 | PHARMACEUTICAL USE OF SUBSTITUTED 1,2,4-TRIAZOLES | NOVO NORDISK A/S (DK) | 2006-01-18 | — | — | EP | claimed |
| WO-2004089416-A2 | COMBINATION OF AN 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND AN ANTIHYPERTENSIVE AGENT | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | claimed |
| WO-2004089367-A1 | PHARMACEUTICAL USE OF SUBSTITUTED 1,2,4-TRIAZOLES | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | claimed |
| WO-2004089415-A2 | COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | claimed |
| US-20230136150-A1 | Compositions for Inhibition of Insect Sensing | UNIV VANDERBILT (US) | 2023-05-04 | — | — | US | disclosed |
| US-20210219551-A1 | Compositions for Inhibition of Insect Sensing | VANDERBILT UNIVERSITY | 2021-07-22 | — | — | US | disclosed |
| US-10813355-B2 | Compositions for inhibition of insect sensing | VANDERBILT UNIVERSITY (US) | 2020-10-27 | — | — | US | disclosed |
| US-20190075798-A1 | Compositions for Inhibition of Insect Sensing | VANDERBILT UNIVERSITY | 2019-03-14 | — | — | US | disclosed |
| US-20060094699-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy | HIGH POINT PHARMACEUTICALS, LLC | 2006-05-04 | — | — | US | disclosed |
| EP-1615666-A2 | COMBINATION OF AN 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND AN ANTIHYPERTENSIVE AGENT | NOVO NORDISK A/S (DK) | 2006-01-18 | — | — | EP | disclosed |
| EP-1615637-A1 | PHARMACEUTICAL USE OF SUBSTITUTED 1,2,4-TRIAZOLES | NOVO NORDISK A/S (DK) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004089367-A1 | PHARMACEUTICAL USE OF SUBSTITUTED 1,2,4-TRIAZOLES | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004089416-A2 | COMBINATION OF AN 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND AN ANTIHYPERTENSIVE AGENT | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230136150-A1 | Compositions for Inhibition of Insect Sensing | OR51E2, TRPA1, OR10J3 | TSHR 2971/4885ALDH1A1 3579/4885HTT 3745/4885 |
| US-10813355-B2 | Compositions for inhibition of insect sensing | OR51E2, TRPA1, OR10J3 | TSHR 3088/4885ALDH1A1 3568/4885HTT 3893/4885 |
| US-20060094699-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy | HSD11B1, HSD17B1, NR3C1 | TSHR 641/4885ALDH1A1 253/4885HTT 4448/4885 |
| US-20090137574-A1 | Combination Therapy Using an 11Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor and an Antihypertensive Agent for the Treatment of Metabolic Syndrome and Related Diseases and Disorders | HSD11B1, HSD11B2, HSD17B1 | TSHR 2931/4885ALDH1A1 74/4885HTT 2515/4885 |
| US-20060111348-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders | HSD11B1, HSD11B2, HSD17B1 | TSHR 2931/4885ALDH1A1 74/4885HTT 2515/4885 |
| US-20210219551-A1 | Compositions for Inhibition of Insect Sensing | OR51E2, TRPA1, OR10J3 | TSHR 2971/4885ALDH1A1 3579/4885HTT 3745/4885 |
| US-20090264412-A1 | Combination Therapy Using An 11beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor And A Glucocorticoid Receptor Agonist To Minimize The Side Effects Associated With Glucocorticoid Receptor Agonist Therapy | HSD11B1, HSD17B1, NR3C1 | TSHR 641/4885ALDH1A1 253/4885HTT 4448/4885 |
| US-20190075798-A1 | Compositions for Inhibition of Insect Sensing | OR51E2, TRPA1, OR10J3 | TSHR 3088/4885ALDH1A1 3568/4885HTT 3893/4885 |
| US-20060100235-A1 | Pharmaceutical use of substituted 1,2,4-triazoles | HSD3B1, HSD11B1, HSD3B2 | TSHR 2592/4885ALDH1A1 132/4885HTT 3289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.